...Okay. Welcome back, everybody, for our next session at the SVB Securities Healthcare Conference. We are lucky enough to have the management team of Amylyx. We have Josh Cohen and Justin Klee, the two co-founders; and Jim Frates, who is the CFO. We've been supporters of this company since they went public. There's not a lot of ALS drugs out there, and this is a really good drug. And we think it's been a [great move] quite a bit on top of standard of care. So we've been very positive on this thing for quite a while. And it's so much great to have them here. There was a filing that went out, the SEC filing this morning. And so I'm going to throw this over to Josh. He is going to kick off a little bit and probably just give a little comment on what went into that release so we're all level set. And thanks again for everybody joining us. Go ahead, Josh. Josh Cohen ...
